In a report released today, Louise Chen from Scotiabank maintained a Buy rating on Amgen, with a price target of $385.00. Chen covers the Healthcare sector, focusing on stocks such as Bristol-Myers ...

The larger risk reductions were not explained by changes in LDL cholesterol, suggesting something else is at play.

It’s an open-ended index fund replicating the Nasdaq 100 Index. With attractive returns clocked by this index attracting ...

Detailed price information for Teva Pharmaceutical Industries ADR (TEVA-N) from The Globe and Mail including charting and ...

Koen Bijvank of Brinkhof and Johannes Heselberger of Bardehle Pagenberg discuss the Amgen v Sanofi case and why it will be ...

Adding tucatinib (Tukysa) to first-line maintenance therapy with trastuzumab (Herceptin) and pertuzumab (Perjeta) delayed disease progression in patients with HER2-positive metastatic breast cancer, ...

Generic drugmakers face U.S. pricing pressure, but TEVA, SDZNY and RDY gain momentum through complex generics and biosimilars.

Eli Lilly's innovation and pipeline diversification support long-term growth, despite patent risks and competition. Read more ...

Tucatinib addition to trastuzumab and pertuzumab significantly improved PFS in HER2-positive metastatic breast cancer, with a median PFS of 24.9 months versus 16.3 months with placebo. The PFS benefit ...

News of a slowdown in the UK’s clean energy IP landscape and an EPO report on unitary patent uptake were also among the top ...

The European Medicines Agency has recommended the approval of GSK's add-on drug to treat asthma and a chronic inflammatory ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages ...